Aktie A2AFAH SHILPA MEDICARE LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Shilpa Medicare Limited

Aktien

A2AFAH

INE790G01031

SHILPAMED

Verzögert Bombay S.E.
Andere Börsenplätze
 09:12:26 06.05.2024 		% 5 Tage % 1. Jan.
528.6 INR -1.27% Intraday Chart für Shilpa Medicare Limited -1.37% +59.99%
09.04. Shilpa Medicare erhält grünes Licht für QIP MT
28.03. Shilpa Medicare's Life Science Arm ernennt CEO MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US
Shilpa Medicare Gets GMP Certification from Austrian Agency for Telangana, India Unit
Shilpa Medicare Gets Board Nod to Launch QIP
Shilpa Medicare's Life Science Arm Names CEO
Shilpa Medicare's New Unit in Hyderabad, India Gets Zero Observations from US FDA
Shilpa Medicare Gets Approval to Market Smoking Cessation Drug in Europe
Shilpa Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
Shilpa Medicare Gets Germany's Marketing Approval for Rare Muscles Diseases Drug
Shilpa Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
Shilpa Medicare Acquires US-Based Pilnova Pharma
Shilpa Medicare Limited Launches Naturally Derived Option for the Treatment of Oral Mucositis in India Under the Brand Name Oraal
Shilpa Medicare Unit's API Manufacturing Plant Gets Clearance from Japanese Drug Regulator's Inspection
Shilpa Medicare Gets UK Drug Regulator's Nod to Market Drug for Meniere's Syndrome Symptoms
Shilpa Medicare Limited Receives Marketing Authorization from MHRA, UK, for Betahistine Dihydrochloride Orodispersible Films, 24 mg
Shilpa Medicare's Manufacturing Facility in Telangana Gets Clearance from Brazilian Regulator
Shilpa Medicare Limited Reports Earnings Results for the First Quarter Ended June 30, 2023
Shilpa Medicare Limited Announces Issuance of Redeemable Non-Convertible Debentures for its 2 Wholly Owned Subsidiaries
Shilpa Medicare Gets Regulatory Nod for Pemetrexed Injections
Shilpa Medicare Limited Receives Approval from CDSCO, New Delhi for Manufacturing and Sale of Lenvatinib Capsules, 12, 18 and 24 mg in India
Shilpa Medicare to Raise Up to INR3.25 Billion from Rights Issue
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2AFAH Aktie
  4. Nachrichten Shilpa Medicare Limited
  5. Andere Sprachen